Samuel E. Lynch, D.M.D., D.M.Sc.
President and Chief Executive Officer
Dr. Lynch is founder of BioMimetic and has been its president, CEO and a director since inception in 1999. He also served as chairman of the board from inception until August 2005. Dr. Lynch has spent his career in health care management, product development, and earlier in academic medicine/dentistry, including research and patient care. He received his Doctorate of Medical Sciences and Specialty in Periodontology from the Harvard Medical and Dental Schools, respectively, as well as a Doctorate of Dental Medicine from Southern Illinois University School of Dental Medicine. He has published and lectured extensively worldwide and is a co-inventor of BioMimetic’s technologies. In this era of complex regulatory environments he is one of only a handful of doctors to have been fortunate enough to make a breakthrough discovery and oversee its development through all phases of product development culminating in FDA approval and commercialization. Dr. Lynch is a member of the board of directors of GreenBankshares, Inc. and numerous non-profit organizations.
Larry Bullock, MBA
Chief Financial Officer
Mr. Bullock joined BioMimetic in January 2004 as chief financial officer. From January 1996 to February 2003, Mr. Bullock served as chief financial officer of Ribozyme Pharmaceuticals Inc., now called Sirna Pharmaceuticals Inc., and as chief financial officer of La Jolla Pharmaceuticals for five years prior to joining Sirna. He led both companies through their private to public transitions, completing private and initial public offerings and building the public reporting team. Mr. Bullock received his MBA from the University of Utah and his B.A. from Indiana University.
Senior Vice President, Research and Development/Protein Chemistry
Mr. Snel joined BioMimetic in August 2007 and is senior vice president of R&D protein biochemistry. He brings 30 years of protein science and product development expertise to BioMimetic, most recently at Amgen leading a Global Operations team to launch Amgen's first oncology protein therapeutic, Vectibix. Mr. Snel also led the CMC section filing of the BLA (Biologics License Application) and PLA (Production Facility License Application) for Vectibix, an antibody to treat late stage colorectal cancer. Prior to that, Mr. Snel spent two years at ZymoGenetics as senior director of analytical sciences and contract manufacturing, and 24 years at NovoNordisk where he held a variety of positions, including 6 years as director of biologics development for the health care Division and was involved in regulatory filings worldwide involving recombinant insulins, liquid formulation of growth hormones (hGH Simplexx) and blood factor VII (NovoSevenn). He received his MSc from the Technical University of Denmark and a Diploma in Drug & Device Development from the Scandinavian International Management Institute.
Vice President, Clinical Research
William Beasley joined BioMimetic in 2001 and is vice president, clinical affairs. He previously served five years in clinical trials management at Covance, Inc., a large, multinational Clinical Research Organization (CRO) where he directed phase I - phase III clinical trials for major international pharmaceutical companies. In his current position, Mr. Beasley led the Company’s pivotal and pilot trials in multiple therapeutic areas, including periodontics and orthopedics. He has implemented an electronic data capture (EDC) instrument developed by a small CRO into the Company's clinical program, substantially improving clinical trial efficiencies. Mr. Beasley's clinical research management experience includes a diverse range of pharmaceuticals, biologics, medical devices and combination products.
Vice President, Orthopedics and Sports Medicine
Hans Kestler joined BioMimetic in 2006 as director of its orofacial healthcare business and was promoted to vice president, sports medicine in 2008 and then to vice president, orthopedics and sports medicine in early 2011. As director of orofacial healthcare, Mr. Kestler was responsible for both product and business development in support of the Company's first approved product, GEM 21S. Upon successfully leading the divestiture of the orofacial business to Luitpold Pharmaceuticals in early 2008, Mr. Kestler assumed leadership of a focused team pursuing the use of rhPDGF-BB in cartilage, tendon and ligament applications. More recently, Mr. Kestler’s role has expanded to also include certain management functions related to the Company’s orthopedics business. Mr. Kestler's prior management experience includes leadership responsibilities in marketing, sales and product development in several medical device/tissue engineering therapeutic areas.
Vice President, Global Sales and Marketing
Mr. Scott Ludecker joined the company in February 2011 as vice president of global sales and marketing. Previously, he served as senior vice president of the lower limb business unit for Small Bone Innovations (SBi), a company he joined in June of 2005, where he oversaw sales and marketing functions in the company’s rapidly expanding lower extremity businesses. Prior to joining SBi, Mr. Ludecker served in a variety of sales and marketing leadership positions with Smith and Nephew’s orthopaedics trauma division for five years. Throughout his career, Mr. Ludecker has demonstrated strong leadership skills and experience in building high performance sales and marketing organizations in the orthopedic industry.
Senior Vice President, Operations
Mr. Monsor joined BioMimetic in 2002 and is senior vice president, operations. Mr. Monsor spent 15 years in positions of increasing responsibility at Abbott Laboratories within operations and quality. Following Abbott, he was director of product supply for ALK-Abello, where he was responsible for the entire product supply chain for U.S. operations. He has had responsibility for all aspects of supply chain management, quality assurance, quality control, regulatory affairs, customer service, facilities management, construction management, and HR. His experience includes Aseptic Processing, Medical Devices, and Bulk Pharmaceuticals. Mr. Monsor received his B.S. from the University of California, Irvine.
Russ Pagano, Ph.D.
Vice President, Clinical and Regulatory Affairs
Dr. Pagano joined the Company in May 2007 in the position of vice president of regulatory and clinical affairs. Dr. Pagano joined the U.S. Food and Drug Administration ("FDA") as a scientific reviewer in the Office of Device Evaluation in 1994. He served as FDA chief of the Restorative Devices Branch, which included a portion of the organization's orthopedic products from 1997 to 2000. While leading this branch, he reviewed bone graft substitute and bone morphogenetic protein (BMP) products from companies such as Medtronic and Stryker. He also held the position of FDA chief of the Pacing, Defibrillators and Leads Branch from October 2000 to May 2001. Since that time, he has been executive vice president and regulatory advisor at M Squared Associates, a consulting firm in Washington D.C. In that capacity, Dr. Pagano served as a regulatory consultant to BioMimetic and numerous other companies and helped prepare PMAs for filing and provided panel preparation services. Dr. Pagano received his Ph.D from Duke University.